The Future of Dialysis and Kidney Xenotransplantation: Promise, Cost, and Barriers to Implementation
Journal of Clinical Medicine · 30.10.2026 · 15 (21) · 8464
DOI: 10.3390/jcm15218464 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.10.2026. Verfasst von Carmine Zoccali und 3 weiteren Autor:innen. Beteiligte Einrichtung: Renal Research Institute, New York, NY 10065, USA. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Dialysis remains essential for patients with kidney failure but replaces only part of kidney function and imposes a substantial treatment burden. Gene-edited porcine kidneys offer a possible additional source of organs, although clinical experience remains limited. This review examines advances in dialysis and kidney xenotransplantation, their evidence base, costs, and barriers to clinical use.
Methods
We undertook a targeted narrative update of clinical and technological reports, economic studies, and regulatory material. Randomized trials were considered separately from observational studies, target trial emulations, individual cases, preclinical experiments, and economic projections.
Results
Randomized evidence supports a survival benefit of high-volume hemodiafiltration in suitable patients, although individual trials have differed and achieved convection volume is influenced by patient and treatment characteristics. Wearable dialysis and sorbent-assisted peritoneal dialysis remain at an early stage of clinical evaluation. Porcine kidney xenografts have provided dialysis independence in individual recipients, but rejection, endothelial injury, infection, and the burden of immunosuppression remain unresolved. Human kidney transplantation is generally favorable over longer horizons in eligible patients; its value depends on the setting. Xenotransplantation costs and long-term cost-effectiveness remain uncertain. Implementation requires financing, trained staff, reliable supply chains, and informed consent that addresses prolonged surveillance and cultural concerns.
Conclusions
Improved dialysis and kidney xenotransplantation are likely to have complementary roles. Adoption should depend on demonstrated clinical benefit, sustainable costs, and equitable access, while prevention and early treatment of chronic kidney disease remain priorities.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Renal Research Institute, New York, NY 10065, USA.
- Istituto di Biologia e Genetica Molecolare (BIOGEM), 83031 Ariano Irpino, Italy.
- Associazione Ipertensione Nefrologia e Trapianto Renale (IPNET), 89124 Reggio Calabria, Italy.
- National Research Council-Institute of Clinical Physiology, 89124 Reggio Calabria, Italy.
- Global Medical Office, Fresenius Medical Care, 26010 Palazzo Pignano, Italy.
ORCID-Profile: Stefano Stuard
Zitieren
APA
Zoccali, C., Mallamaci, F., Tripepi, G., & Stuard, S. (2026). The Future of Dialysis and Kidney Xenotransplantation: Promise, Cost, and Barriers to Implementation. Journal of Clinical Medicine, 15(21), 8464. https://doi.org/10.3390/jcm15218464
Vancouver
Zoccali C, Mallamaci F, Tripepi G, Stuard S. The Future of Dialysis and Kidney Xenotransplantation: Promise, Cost, and Barriers to Implementation. Journal of Clinical Medicine. 2026;15(21):8464. doi:10.3390/jcm15218464
BibTeX
@article{Zoccali2026,
author = {Zoccali, Carmine and Mallamaci, Francesca and Tripepi, Giovanni and Stuard, Stefano},
title = {The Future of Dialysis and Kidney Xenotransplantation: Promise, Cost, and Barriers to Implementation},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8464},
doi = {10.3390/jcm15218464}
}
EUVIMED